Biomarkers of Gemtuzumab Ozogamicin Response ...
Document type :
Article dans une revue scientifique: Article original
DOI :
PMID :
Title :
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
Author(s) :
Fenwarth, Laurène [Auteur]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Institut de Pathologie [CHU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Fournier, Elise [Auteur]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Cheok, Meyling [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Boyer, Thomas [Auteur]
CHU Amiens-Picardie
Gonzales, Fanny [Auteur]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Castaigne, Sylvie [Auteur]
Boissel, Nicolas [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Hopital Saint-Louis [AP-HP] [AP-HP]
Lambert, Juliette [Auteur]
Dombret, Herve [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Université Paris Diderot - Paris 7 [UPD7]
Preudhomme, Claude [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Duployez, Nicolas [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Institut de Pathologie [CHU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Fournier, Elise [Auteur]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Cheok, Meyling [Auteur]

Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Boyer, Thomas [Auteur]
CHU Amiens-Picardie
Gonzales, Fanny [Auteur]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Castaigne, Sylvie [Auteur]
Boissel, Nicolas [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Hopital Saint-Louis [AP-HP] [AP-HP]
Lambert, Juliette [Auteur]
Dombret, Herve [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Université Paris Diderot - Paris 7 [UPD7]
Preudhomme, Claude [Auteur]

Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Duployez, Nicolas [Auteur]

Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Journal title :
International Journal of Molecular Sciences
Pages :
5626
Publisher :
MDPI
Publication date :
2020
ISSN :
1661-6596
English keyword(s) :
CD33
FLT3
acute myeloid leukemia
biomarkers
gemtuzumab ozogamicin
therapy
FLT3
acute myeloid leukemia
biomarkers
gemtuzumab ozogamicin
therapy
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Gemtuzumab ozogamicin (GO, Mylotarg(R)) consists of a humanized CD33-targeted antibody-drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute myeloid leukemia (AML), demonstrated by improved ...
Show more >Gemtuzumab ozogamicin (GO, Mylotarg(R)) consists of a humanized CD33-targeted antibody-drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute myeloid leukemia (AML), demonstrated by improved outcomes in CD33-positive AML patients across phase I to III clinical trials, led to the Food and Drug Administration (FDA) approval on 1 September 2017 in CD33-positive AML patients aged 2 years and older. Discrepancies in GO recipients outcome have raised significant efforts to characterize biomarkers predictive of GO response and have refined the subset of patients that may strongly benefit from GO. Among them, CD33 expression levels, favorable cytogenetics (t(8;21), inv(16)/t(16;16), t(15;17)) and molecular alterations, such asNPM1,FLT3-internal tandem duplications and other signaling mutations, represent well-known candidates. Additionally, in depth analyses including minimal residual disease monitoring, stemness expression (LSC17 score), mutations or single nucleotide polymorphisms in GO pathway genes (CD33,ABCB1) and molecular-derived scores, such as the recently set up CD33_PGx6_Score, represent promising markers to enhance GO response prediction and improve patient management.Show less >
Show more >Gemtuzumab ozogamicin (GO, Mylotarg(R)) consists of a humanized CD33-targeted antibody-drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute myeloid leukemia (AML), demonstrated by improved outcomes in CD33-positive AML patients across phase I to III clinical trials, led to the Food and Drug Administration (FDA) approval on 1 September 2017 in CD33-positive AML patients aged 2 years and older. Discrepancies in GO recipients outcome have raised significant efforts to characterize biomarkers predictive of GO response and have refined the subset of patients that may strongly benefit from GO. Among them, CD33 expression levels, favorable cytogenetics (t(8;21), inv(16)/t(16;16), t(15;17)) and molecular alterations, such asNPM1,FLT3-internal tandem duplications and other signaling mutations, represent well-known candidates. Additionally, in depth analyses including minimal residual disease monitoring, stemness expression (LSC17 score), mutations or single nucleotide polymorphisms in GO pathway genes (CD33,ABCB1) and molecular-derived scores, such as the recently set up CD33_PGx6_Score, represent promising markers to enhance GO response prediction and improve patient management.Show less >
Language :
Anglais
Peer reviewed article :
Oui
Audience :
Internationale
Popular science :
Non
ANR Project :
Collections :
Source :
Files
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460695/pdf
- Open access
- Access the document
- Open access
- Access the document
- document
- Open access
- Access the document
- ijms-21-05626.pdf
- Open access
- Access the document
- document
- Open access
- Access the document
- ijms-21-05626.pdf
- Open access
- Access the document
- document
- Open access
- Access the document
- ijms-21-05626.pdf
- Open access
- Access the document